Surgery-based treatment and prognostic factors in patients with limited-stage small cell lung cancer: a retrospective cohort study - Takeaways - MDSpire

Surgery-based treatment and prognostic factors in patients with limited-stage small cell lung cancer: a retrospective cohort study

  • By

  • Mingbo Wang

  • Heng Zhao

  • Yuefeng Zhang

  • Huilai Lv

  • Qin Chu

  • Yonggang Zhu

  • Chunyue Gai

  • Ziqiang Tian

  • May 13, 2026

  • 0 min

Share

  • 1

    This study analyzed 103 patients with limited-stage small cell lung cancer who underwent complete R0 resection and adjuvant therapy.

  • 2

    The median overall survival was 81 months, with a 5-year overall survival rate of 58.3% and a median disease-free survival of 50 months.

  • 3

    Patients with stage I-IIA disease had significantly better survival outcomes compared to those with stage IIB-IIIB disease.

  • 4

    Advanced pathological TNM stage was identified as an independent adverse prognostic factor, while adjuvant chemotherapy plus radiotherapy improved survival.

  • 5

    Postoperative brain metastasis was linked to significantly poorer outcomes, highlighting the need for effective post-treatment monitoring.

Original Source(s)

Surgery-based treatment and prognostic factors in patients with limited-stage small cell lung cancer: a retrospective cohort study

  • by Mingbo Wang, Heng Zhao, Yuefeng Zhang, Huilai Lv, Qin Chu, Yonggang Zhu, Chunyue Gai, Ziqiang Tian

  • May 13, 2026

Related Content

Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices

Machine learning–based prediction of mortality in lung cancer: Application of severity-adjustment method

Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy